The historical rank and industry rank for Acorda Therapeutics's FCF Margin % or its related term are showing as below:
ACORQ'
s FCF Margin % Range Over the Past 10 Years
Min: -113.61 Med: -24.97 Max: 24.79
Current: -11.89
During the past 13 years, the highest FCF Margin % of Acorda Therapeutics was 24.79%. The lowest was -113.61%. And the median was -24.97%.
ACORQ's FCF Margin % is ranked worse than 69.59% of 1026
companies
in the Drug Manufacturers industry
Industry Median: -0.68
vs ACORQ: -11.89
Acorda Therapeutics FCF Margin % Historical Data
The historical data trend for Acorda Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acorda Therapeutics's FCF Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's FCF Margin % falls into.
Acorda Therapeutics FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Acorda Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics FCF Margin % Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 